- |||||||||| recombinant human erythropoietin / Max Planck Institute, Pfizer
Review, Journal: Neuroprotective Effects of Moderate Hypoxia: A Systematic Review. (Pubmed Central) - Dec 23, 2023
We identified 58 eligible studies (k = 8 human studies with N = 274 individuals; k = 48 animal studies) reporting the effects of hypoxia on cognition, motor function, neuroimaging, neuronal/synaptic morphology, inflammation, oxidative stress, erythropoietin, neurotrophins, and Alzheimer's disease markers...Low-dose intermittent or continuous hypoxia repeated for 30-240 min sessions, preferably in combination with motor-cognitive training, produced beneficial effects, and high-dose hypoxia with longer (?6 h) durations and chronic exposure produced more adverse effects. Larger and methodologically stronger translational studies are warranted.
- |||||||||| recombinant human erythropoietin / Max Planck Institute, Pfizer
Pro-cognitive effects of intravenous erythropoietin in patientswith schizophrenia () - Mar 10, 2023 - Abstract #SIRS2023SIR_260;
Nonetheless, EPO constitutes a promisingapproach to mitigate cognitive deficits in several patient groups allowing to improve functionaloutcome. Hence, further efforts to establish optimal administration protocols and to promote awidespread use should be supported.KeywordKeywordsCognitive Decline in SchizophreniaPharmacological Treatmentneurodevelopmental disorderspsychosis, cognition, negative symptoms, neurobiologyPoster Award YesPoster Award Eligibility - Young Investigator YesPoster Award Eligibility - SIRS Membership NoPlease list all co-authors for this poster submission.* Presenting AuthorFirst Name Last Name AffiliationMishal * Qubad * Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe University2Karlotta Jacobs Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityCatherine Barnes-Scheufler Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityMareike Aichholzer Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannah Wendy Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannelore Ehrenreich Clinical Neuroscience, Max PlanckInstitute of Experimental Medicine,G
- |||||||||| recombinant human erythropoietin / Max Planck Institute, Pfizer
Journal: For decades against the mainstream - From erythropoietin and hypoxia as novel treatment strategies to deep phenotyping in neuropsychiatric disorders. (Pubmed Central) - Nov 18, 2022
Hence, further efforts to establish optimal administration protocols and to promote awidespread use should be supported.KeywordKeywordsCognitive Decline in SchizophreniaPharmacological Treatmentneurodevelopmental disorderspsychosis, cognition, negative symptoms, neurobiologyPoster Award YesPoster Award Eligibility - Young Investigator YesPoster Award Eligibility - SIRS Membership NoPlease list all co-authors for this poster submission.* Presenting AuthorFirst Name Last Name AffiliationMishal * Qubad * Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe University2Karlotta Jacobs Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityCatherine Barnes-Scheufler Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityMareike Aichholzer Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannah Wendy Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannelore Ehrenreich Clinical Neuroscience, Max PlanckInstitute of Experimental Medicine,G No abstract available
- |||||||||| recombinant human erythropoietin / Max Planck Institute, Pfizer
Clinical, Journal: Brain erythropoietin fine-tunes a counterbalance between neurodifferentiation and microglia in the adult hippocampus. (Pubmed Central) - Feb 12, 2022
Surprisingly, EPO affects microglia in phases, initially by inducing apoptosis, later by reducing proliferation, and overall dampens microglia activity and metabolism, as verified by selective genetic targeting of either the microglial or pyramidal neuronal EPO receptor. We suggest that during accelerating neuronal differentiation, EPO acts as regulator of the CSF1R-dependent microglia.
- |||||||||| recombinant human erythropoietin / Trillium Therap, Max Planck Institute
Journal: CaMKIIα Expressing Neurons to Report Activity-Related Endogenous Hypoxia upon Motor-Cognitive Challenge. (Pubmed Central) - May 13, 2021
We previously introduced the brain erythropoietin (EPO) circle as a model to explain the adaptive 'brain hardware upgrade' and enhanced performance...To conclude, task-associated activity triggers neuronal functional hypoxia as a local and brain-wide reaction mediating adaptive neuroplasticity. Hypoxia-induced genes such as EPO drive neuronal differentiation, brain maturation, and improved performance.
|
